Equities analysts predict that AxoGen, Inc. (NASDAQ:AXGN) will post $16.07 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for AxoGen’s earnings. The lowest sales estimate is $15.70 million and the highest is $16.50 million. AxoGen reported sales of $11.41 million during the same quarter last year, which indicates a positive year-over-year growth rate of 40.8%. The business is scheduled to issue its next earnings results on Wednesday, February 28th.
On average, analysts expect that AxoGen will report full year sales of $16.07 million for the current financial year, with estimates ranging from $59.20 million to $60.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $83.77 million per share, with estimates ranging from $83.50 million to $84.20 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover AxoGen.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $16.05 million during the quarter, compared to the consensus estimate of $15.55 million. AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The company’s revenue for the quarter was up 43.2% on a year-over-year basis.
AxoGen (AXGN) traded down $0.35 during mid-day trading on Tuesday, reaching $27.75. 198,500 shares of the company traded hands, compared to its average volume of 338,000. The firm has a market capitalization of $958.04, a P/E ratio of -69.38 and a beta of 0.40. AxoGen has a 1-year low of $8.75 and a 1-year high of $31.70. The company has a quick ratio of 2.95, a current ratio of 3.55 and a debt-to-equity ratio of 1.93.
In other AxoGen news, Director Jamie Mark Grooms sold 21,290 shares of the business’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $26.22, for a total value of $558,223.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $19.74, for a total value of $22,701,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,293,990 shares of company stock worth $26,494,898. 9.33% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of AxoGen by 9.0% during the second quarter. Vanguard Group Inc. now owns 1,223,069 shares of the medical equipment provider’s stock valued at $20,486,000 after acquiring an additional 101,245 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of AxoGen by 293.9% in the third quarter. Bank of New York Mellon Corp now owns 631,563 shares of the medical equipment provider’s stock worth $12,222,000 after purchasing an additional 471,209 shares during the last quarter. State Street Corp boosted its position in AxoGen by 19.6% during the 2nd quarter. State Street Corp now owns 438,641 shares of the medical equipment provider’s stock valued at $7,350,000 after acquiring an additional 71,752 shares in the last quarter. Castleark Management LLC bought a new stake in AxoGen during the 2nd quarter valued at approximately $5,426,000. Finally, Northern Trust Corp boosted its position in AxoGen by 7.8% during the 2nd quarter. Northern Trust Corp now owns 308,360 shares of the medical equipment provider’s stock valued at $5,165,000 after acquiring an additional 22,319 shares in the last quarter. Hedge funds and other institutional investors own 66.08% of the company’s stock.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.